Primary Myelofibrosis
Showing 26 - 50 of >10,000
Myelofibrosis Trial in Saint Louis (Fostamatinib, Ruxolitinib)
Recruiting
- Myelofibrosis
-
Saint Louis, MissouriWashington University School of Medicine
Oct 26, 2022
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Myelofibrosis Trial in Hangzhou (Jaktinib Hydrochloride Tablets)
Recruiting
- Myelofibrosis
- Jaktinib Hydrochloride Tablets
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
Nov 28, 2022
Myelofibrosis Trial in Hong Kong (Bomedemstat)
Recruiting
- Myelofibrosis
-
Hong Kong, Hong KongDepartment of Medicine, the University of Hong Kong, Queen Mary
Oct 3, 2022
Myelofibrosis Trial in Hangzhou (Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets)
Recruiting
- Myelofibrosis
- Jaktinib
- +3 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
Nov 28, 2022
Myelofibrosis Trial in Changsha (Jaktinib Hydrochloride Tablets)
Not yet recruiting
- Myelofibrosis
- Jaktinib Hydrochloride Tablets
-
Changsha, Hunan, ChinaThe Third Hospital of Changsha
Nov 9, 2023
Myelofibrosis Trial in Jinan (Ruxolitinib)
Recruiting
- Myelofibrosis
-
Jinan, Shandong, ChinaQilu Hospital of Shandong University
Jul 3, 2022
Myelofibrosis Due to and Following Polycythemia Vera Trial in United States (Ruxolitinib, Abemaciclib)
Recruiting
- Myelofibrosis Due to and Following Polycythemia Vera
-
Basking Ridge, New Jersey
- +6 more
Jan 26, 2023
Myelofibrosis Trial in Houston (Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib)
Active, not recruiting
- Myelofibrosis
- Long-term Follow-up
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 7, 2022
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome Trial in Duarte (Fludarabine, Itacitinib Adipate,
Active, not recruiting
- Acute Leukemia
- +4 more
- Fludarabine
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Myelofibrosis Trial in Changchun (TQ05105 Tablets)
Completed
- Myelofibrosis
- TQ05105 Tablets
-
Changchun, Jilin, ChinaAffiliated Hospital of Changchun University of Traditional Chine
Aug 1, 2023
Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis Trial in Buffalo (drug, dietary supplement, other)
Terminated
- Essential Thrombocythemia
- +2 more
- Arsenic Trioxide
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Scottsdale (Laboratory Biomarker Analysis, Quality-of-Life Assessment,
Active, not recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Laboratory Biomarker Analysis
- +2 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 7, 2022
Myelofibrosis, Chronic Myelomonocytic Leukemia Trial in Canada, United States (SL-401)
Active, not recruiting
- Myelofibrosis
- Chronic Myelomonocytic Leukemia
-
Duarte, California
- +9 more
Jan 24, 2023
Myeloproliferative Tumor, MPN, Essential Thrombocythemia Trial in Orange (N-Acetylcysteine)
Active, not recruiting
- Myeloproliferative Neoplasm
- +4 more
-
Orange, CaliforniaChao Family Comprehensive Cancer Center, University of Californi
Jan 6, 2023